These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3848476)

  • 1. Aluminum bone disease. (A case study).
    Coleman S
    J Nephrol Nurs; 1985; 2(3):125-6. PubMed ID: 3848476
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypercalcaemic osteomalacia and encephalopathy due to aluminium intoxication in haemodialysis patients. Clinical aspects and treatment with desferrioxamine.
    Mudde AH; Roodvoets AP; Van Groningen K
    Neth J Med; 1985; 28(1):6-11. PubMed ID: 3974771
    [No Abstract]   [Full Text] [Related]  

  • 3. Changes in bone histology after treatment with desferrioxamine.
    Ott SM; Andress DL; Nebeker HG; Milliner DS; Maloney NA; Coburn JW; Sherrard DJ
    Kidney Int Suppl; 1986 Feb; 18():S108-13. PubMed ID: 3457986
    [No Abstract]   [Full Text] [Related]  

  • 4. Improvement of anemia with deferoxamine in hemodialysis patients with aluminum-induced bone disease.
    Tielemans C; Collart F; Wens R; Smeyers-Verbeeke J; van Hooff I; Dratwa M; Verbeelen D
    Clin Nephrol; 1985 Nov; 24(5):237-41. PubMed ID: 4075595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
    Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984
    [No Abstract]   [Full Text] [Related]  

  • 6. Aluminum-induced dialysis osteodystrophy: the demise of "Newcastle bone disease"?
    Kerr DN; Ward MK; Arze RS; Ramos JM; Grekas D; Parkinson IS; Ellis HA; Owen JP; Simpson W; Dewar J
    Kidney Int Suppl; 1986 Feb; 18():S58-64. PubMed ID: 3457998
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of dialysis encephalopathy with deferoxamine].
    Starkstein S; Berthier M; Nogués M; Leiguarda R
    Medicina (B Aires); 1986; 46(3):327-31. PubMed ID: 3574092
    [No Abstract]   [Full Text] [Related]  

  • 8. [Serum aluminum in hemodialysis patients. Relation to osteodystrophy, encephalopathy and aluminum hydroxide consumption].
    Nielsen LP; Heaf JG
    Ugeskr Laeger; 1983 May; 145(18):1363-7. PubMed ID: 6868163
    [No Abstract]   [Full Text] [Related]  

  • 9. Aluminum intoxication of bone in renal failure--fact or fiction?
    Malluche HH; Faugere MC; Smith AJ; Friedler RM
    Kidney Int Suppl; 1986 Feb; 18():S70-3. PubMed ID: 3458000
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical and biochemical features of aluminum-related bone disease.
    Ihle BU; Becker GJ; Kincaid-Smith PS
    Kidney Int Suppl; 1986 Feb; 18():S80-6. PubMed ID: 3458003
    [No Abstract]   [Full Text] [Related]  

  • 11. [Osteomalacia induced by aluminum in a patient under chronic hemodialysis: successful treatment with desferrioxamine].
    Espinoza O; Gehrung E; Roessler E; Katz E; Pérez A; Delmastro J
    Rev Med Chil; 1986 Sep; 114(9):867-71. PubMed ID: 3575972
    [No Abstract]   [Full Text] [Related]  

  • 12. [Aluminum-induced osteomalacia in chronic hemodialysis].
    Smetana S; Popovtzer MM; Bar-Khayim Y
    Harefuah; 1987 Jun; 112(12):595-7. PubMed ID: 3428727
    [No Abstract]   [Full Text] [Related]  

  • 13. Osteomalacia and bone disease arising from aluminum.
    Coburn JW; Norris KC; Nebeker HG
    Semin Nephrol; 1986 Mar; 6(1):68-89. PubMed ID: 3110896
    [No Abstract]   [Full Text] [Related]  

  • 14. Aluminum-related osteomalacia in renal-failure patients.
    Vick KE; Johnson CA
    Clin Pharm; 1985; 4(4):434-9. PubMed ID: 3899471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of aluminium toxicity in a 'low incidence' area.
    Winney RJ; Cowie JF; Cumming AD; Short AI; Smith GD; Robson JS
    Contrib Nephrol; 1984; 38():47-58. PubMed ID: 6713900
    [No Abstract]   [Full Text] [Related]  

  • 16. [Bone mineral content and treatment with deferoxamine in patients under chronic hemodialysis].
    Zanchetta JR; Bogado CE; Zuchini A; Firmat J
    Medicina (B Aires); 1992; 52(2):184-5. PubMed ID: 1308914
    [No Abstract]   [Full Text] [Related]  

  • 17. Fracture healing with deferoxamine therapy in a patient with aluminum-associated osteomalacia.
    Phelps KR; Einhorn TA; Vigorita VJ; Lundin AP; Friedman EA
    ASAIO Trans; 1986; 32(1):198-200. PubMed ID: 3778712
    [No Abstract]   [Full Text] [Related]  

  • 18. [Desferrioxamine treatment of osteomalacia caused by aluminum poisoning].
    Charhon SA; Chavassieux P; Chapuy MC; Accominotti M; Traeger J; Meunier PJ
    Presse Med; 1986 Jan; 15(2):55-9. PubMed ID: 2935857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accumulation of aluminum in a nondialyzed uremic child receiving aluminum hydroxide.
    Griswold WR; Reznik V; Mendoza SA; Trauner D; Alfrey AC
    Pediatrics; 1983 Jan; 71(1):56-8. PubMed ID: 6848980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Aluminum and iron deposition in dialysis patients].
    Kashiwagi T; Kurihara S
    Nihon Rinsho; 2004 Jun; 62 Suppl 6():400-5. PubMed ID: 15250334
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.